Immediate Impact
5 from Science/Nature 71 standout
Citing Papers
Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
T Cell Exhaustion
2024 Standout
Works of Dennis Earle being referenced
CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma.
2019
Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Dennis Earle | 208 | 246 | 35 | 95 | 13 | 430 | |
| Susan Stanik Davis | 367 | 213 | 8 | 18 | 8 | 481 | |
| Steven M. Toler | 109 | 184 | 82 | 21 | 17 | 510 | |
| K Suchecka-Rachoń | 258 | 133 | 39 | 7 | 10 | 452 | |
| Suzanne Clarke | 242 | 63 | 4 | 22 | 9 | 448 | |
| Mari Murashita | 174 | 54 | 18 | 96 | 16 | 445 | |
| David E. Garza | 223 | 86 | 7 | 10 | 7 | 382 | |
| Silvia Donati | 239 | 268 | 6 | 26 | 7 | 479 | |
| Marvin C. Hallberg | 243 | 35 | 37 | 21 | 17 | 489 | |
| Stanley Hertz | 47 | 160 | 21 | 44 | 11 | 471 | |
| Donald M. Barnett | 188 | 142 | 5 | 12 | 6 | 422 |
All Works
Loading papers...